T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$1.36B |
| 2 |
Philip Morris
PM
|
+$1.3B |
| 3 |
Amazon
AMZN
|
+$1.21B |
| 4 |
Stryker
SYK
|
+$1.12B |
| 5 |
AET
Aetna Inc
AET
|
+$1.08B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$1.46B |
| 2 |
Gilead Sciences
GILD
|
+$1.1B |
| 3 |
Walt Disney
DIS
|
+$866M |
| 4 |
Akamai
AKAM
|
+$703M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.69% |
| 2 | Consumer Discretionary | 15.01% |
| 3 | Financials | 13.64% |
| 4 | Technology | 12.55% |
| 5 | Industrials | 10.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
IQVIA
IQV
$39.8B
| $8.33M | ﹤0.01% |
127,916
+16,050
| +14% | +$1.02M |
|
1302
iShares MSCI India ETF
INDA
$6.58B
| $8.32M | ﹤0.01% |
306,900
+30,700
| +11% | +$784K |
|
1303
Fabrinet
FN
$20.3B
| $8.3M | ﹤0.01% |
256,650
-165,870
| -39% | -$4.46M |
|
|
FLIR
1304
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $8.27M | ﹤0.01% |
251,110
+22,200
| +10% | +$686K |
|
|
CLCD
1305
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
| $8.23M | ﹤0.01% |
1,328,115
-19,780
| -1% | -$124K |
|
|
GRMN
1306
Garmin
GRMN
$60.2B
| $8.16M | ﹤0.01% |
204,190
-2,400
| -1% | -$89.1K |
|
1307
Zions Bancorporation
ZION
$10.5B
| $8.15M | ﹤0.01% |
336,773
-2,180
| -0.6% | -$50.1K |
|
1308
Toll Brothers
TOL
$14B
| $8.14M | ﹤0.01% |
275,981
+35,800
| +15% | +$1M |
|
|
OXFD
1309
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $8.14M | ﹤0.01% |
821,446
-1,100
| -0.1% | -$11.3K |
|
1310
Crawford & Co Class A
CRD.A
$632M
| $8.12M | ﹤0.01% |
1,349,327
+151,060
| +13% | +$719K |
|
1311
Gray Television
GTN
$520M
| $8.01M | ﹤0.01% |
683,400
+208,700
| +44% | +$2.57M |
|
1312
Warner Bros
WBD
$69.6B
| $7.94M | ﹤0.01% |
277,240
-80
| -0% | -$2.14K |
|
|
ABAX
1313
DELISTED
Abaxis Inc
ABAX
| $7.93M | ﹤0.01% |
174,660
+1,400
| +0.8% | +$62.2K |
|
1314
Xencor
XNCR
$1.71B
| $7.74M | ﹤0.01% |
576,516
-3,830
| -0.7% | -$45.3K |
|
|
WIBC
1315
DELISTED
WILSHIRE BANCORP INC
WIBC
| $7.69M | ﹤0.01% |
746,720
+74,400
| +11% | +$764K |
|
1316
Stepan Co
SCL
$1.48B
| $7.69M | ﹤0.01% |
139,088
-600
| -0.4% | -$28.9K |
|
|
TVPT
1317
DELISTED
Travelport Worldwide Limited
TVPT
| $7.5M | ﹤0.01% |
+549,400
| New | +$6.6M |
|
1318
Quanta Services
PWR
$101B
| $7.46M | ﹤0.01% |
330,780
-8,710
| -3% | -$173K |
|
1319
Howard Hughes
HHH
$4.04B
| $7.42M | ﹤0.01% |
73,541
+5,035
| +7% | +$463K |
|
1320
Core Laboratories
CLB
$569M
| $7.33M | ﹤0.01% |
65,200
-3,500
| -5% | -$364K |
|
1321
Pitney Bowes
PBI
$2.28B
| $7.33M | ﹤0.01% |
340,071
-4,210
| -1% | -$80K |
|
1322
Children's Place
PLCE
$53.4M
| $7.3M | ﹤0.01% |
87,510
+2,910
| +3% | +$198K |
|
|
WBK
1323
DELISTED
Westpac Banking Corporation
WBK
| $7.27M | ﹤0.01% |
+312,600
| New | +$6.95M |
|
|
PAY
1324
DELISTED
Verifone Systems Inc
PAY
| $7.26M | ﹤0.01% |
256,966
+16,230
| +7% | +$401K |
|
|
JUNO
1325
DELISTED
Juno Therapeutics, Inc.
JUNO
| $7.25M | ﹤0.01% |
190,429
+123,500
| +185% | +$4.3M |
|
Similar funds
T. Rowe Price Associates's Q1 2016 Portfolio in Review
As of Q1 2016, T. Rowe Price Associates held 2,594 positions worth $468B, down 1.5% from $475B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q1 2016 filing shows 78 new, 1,210 increased, 770 reduced and 91 closed positions. Its largest new stake was BRF SA: 5,750,603 shares worth $81.8M. The largest sale was Bausch Health, an estimated $1.46B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2016 buy was BRF SA: 5,750,603 shares worth $81.8M.
- T. Rowe Price Associates added most to NXP Semiconductors in Q1 2016, an estimated $1.36B increase.
- T. Rowe Price Associates's biggest Q1 2016 reduction was Bausch Health, cutting an estimated $1.46B.
- T. Rowe Price Associates fully exited CHUBB CORPORATION in Q1 2016, selling an estimated $496M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $468B portfolio in Q1 2016.
- T. Rowe Price Associates opened 78 new positions and closed 91 in Q1 2016.
- T. Rowe Price Associates's portfolio value fell 1.5% quarter-over-quarter to $468B.
Based on T. Rowe Price Associates's 13F filing for Q1 2016, filed 16 May 2016.